Sam Brusco, Associate Editor06.10.22
Zavation Medical Products has earned U.S. Food and Drug Administration (FDA) 510(k) clearance for its eZspand Lateral expandable lumbar interbody fusion device.
eZspand Lateral features continual expansion for an optimized fit. It doesn’t need secondary locking, which minimizes procedural steps. The cage has up to 15 degrees of lordosis and ability to backfill with bone graft.
Each implant can expand to 6mm from insertion height to create a large graft window.
"Our product development team's dedication to creatively blending simplicity and precision in a robust product design has produced an expandable product that we believe is the new gold standard in facilitating patient fusion in a seamless and simplified procedure," Zavation CEO Jeffrey Johnson told the press. "With restoration of alignment being of critical importance, the eZspand Lateral was developed to help surgeons address stability and sagittal alignment, while maximizing lordotic correction. This product is an example of Zavation's commitment to offering innovative and differentiated products in conjunction with market leading customer service to best serve our surgeons and distributor network."
eZspand interbodies are indicated for spinal fusion procedures to be used with autogenous bone graft in skeletally mature patients. This can be done at either one level or two contiguous levels in the lumbar spine, from L2 to S1, for the treatment of degenerative disc disease (DDD) with up to Grade I spondylolisthesis.
eZspand Lateral features continual expansion for an optimized fit. It doesn’t need secondary locking, which minimizes procedural steps. The cage has up to 15 degrees of lordosis and ability to backfill with bone graft.
Each implant can expand to 6mm from insertion height to create a large graft window.
"Our product development team's dedication to creatively blending simplicity and precision in a robust product design has produced an expandable product that we believe is the new gold standard in facilitating patient fusion in a seamless and simplified procedure," Zavation CEO Jeffrey Johnson told the press. "With restoration of alignment being of critical importance, the eZspand Lateral was developed to help surgeons address stability and sagittal alignment, while maximizing lordotic correction. This product is an example of Zavation's commitment to offering innovative and differentiated products in conjunction with market leading customer service to best serve our surgeons and distributor network."
eZspand interbodies are indicated for spinal fusion procedures to be used with autogenous bone graft in skeletally mature patients. This can be done at either one level or two contiguous levels in the lumbar spine, from L2 to S1, for the treatment of degenerative disc disease (DDD) with up to Grade I spondylolisthesis.